AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

AC Immune S.A.NASDAQ: ACIU

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of CHF 4.17M fell 6.1% year over year, behind the +4.4% change in trailing-twelve-month selling, general & admin. Over 3 fiscal years it compounded at +6.7% a year.

Context

  • Selling, general & admin amounted to 326.1% of revenue in FY2025, up 284.2 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 2 analysts of CHF 35.09M (+201.1%) for the fiscal year ending Dec 2026, a step up from the +1.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 4.17M+1743.3% QoQ
Last fiscal yearDec 2025
CHF 11.65M+1.9% YoY
LTMMar 2026
CHF 11.38M+4.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.1%+1001.1%+1007.2 pp
1 year+1.9%+201.1%+199.2 pp
3-year CAGR+6.7%+143.0%+136.3 pp
5-year CAGR+74.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

CHF · from the income statement

Latest · FY2025
11.65M CHF
Year-over-year change
+1.9%
4-year CAGR
+1.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.4% is the 5th highest of 10, against a peer median of -0.8%.
  • Selling, general & admin amounts to 307.5% of revenue for ACIU, versus a peer median of 2560.2%.
ACIU Competitors
Selling, General & Admin for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.14T USD+9732467.6%-14.5%—
AMRNAmarin Corporation plcLTM Mar 2026$99.54M USD-33.2%-27.7%46.3%
LYELLyell Immunopharma, Inc.LTM Mar 2026$40.64M USD-22.7%-27.3%131109.7%
ANNXAnnexon, Inc.LTM Mar 2026$32.75M USD-0.8%+0.8%—
SLNSilence Therapeutics plcLTM Mar 2026$23.59M USD—+2.2%2560.2%
ANROAlto Neuroscience, Inc.LTM Mar 2026$21.89M USD-3.6%+59.0%—
MREOMereo BioPharma Group plcLTM Mar 2026$19.76M USD-28.1%-0.2%3951.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$17.4M USD+18.2%+41.6%—
ACIUAC Immune S.A.LTM Mar 2026CHF 11.38M CHF+4.4%+6.7%307.5%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$10.42M USD+13.5%-3.1%—
CLLSCellectis S.A.LTM Mar 2026$9.18M USD+20.3%-1.1%13.5%
Peer median (excluding ACIU) —-0.8%-0.7%2560.2%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.94M14.8M27.31M3.57M
Cost of Revenue0054.61M62.57M0
Gross Profit03.94M(39.81M)(35.26M)3.57M
Gross Margin—100.0%-268.9%-129.1%100.0%
Research & Development62.28M60.34M54.61M62.57M56.44M
Selling, General & Admin10.88M9.58M10.58M11.43M11.65M
Operating Expenses79.01M74.78M13.82M17.12M72.44M
Depreciation & Amortization2.41M2.36M2.22M2.16M2.5M
EBITDA(70.01M)(68.03M)(51.83M)(48.62M)(67.75M)
EBITDA Margin—-1728.7%-350.2%-178.0%-1896.2%
Operating Income(79.01M)(70.85M)(53.62M)(52.38M)(68.86M)
Operating Margin—-1800.4%-362.3%-191.8%-1927.3%
Interest Income6.49M69K1.04M3.2M1.87M
Interest Expense581K355K176K133K191K
Other Income / Expenses6.02M107K(599K)1.47M(1.58M)
Income Before Tax(72.99M)(70.74M)(54.22M)(50.91M)(70.45M)
Pre-Tax Margin—-1797.7%-366.3%-186.4%-1971.6%
Income Tax Expense3K13K10K3K0
Net Income(73M)(70.75M)(54.23M)(50.92M)(70.45M)
Net Margin—-1798.0%-366.4%-186.4%-1971.6%
EPS (Basic)(0.97)(0.85)(0.64)(0.51)(0.70)
EPS (Diluted)(0.97)(0.85)(0.64)(0.51)(0.70)
Weighted Avg Shares74.95M83.55M84.69M99.69M100.75M
Weighted Avg Shares (Diluted)74.95M83.55M84.69M99.69M100.75M

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.